Phase Ia/Ib trial of ACH 2928 in volunteers and treatment-naive patients with genotype 1 hepatitis C

Trial Profile

Phase Ia/Ib trial of ACH 2928 in volunteers and treatment-naive patients with genotype 1 hepatitis C

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2012

At a glance

  • Drugs ACH 2928 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2012 Results assessing monotherapy in patients with genotype 1a or 1b hepatitis C have been presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012) according to an Achillion media release.
    • 05 Dec 2011 Preliminary results published in an Achillion Pharmaceuticals media release.
    • 11 Jul 2011 Planned number of patients changed to 68, according to information in an Achillion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top